Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activitie

Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See w

Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NA

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's

Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to l

PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”

Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stag

Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clini

Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinica

Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 acr

PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinica

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinica

Maxim Group analyst Jason McCarthy initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage

Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical developmen

Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical developmen

Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical

Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease

PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage

U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 100 points on

PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-

Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in th

Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology com

PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a c